Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals

被引：0
|
作者：
Austin Lammers
Ruibin Wang
Jeremy Cetnar
Vinay Prasad
机构：
[1] Oregon Health & Science University,Division of Hematology Oncology, Knight Cancer Institute
[2] Johns Hopkins Bloomberg School of Public Health,Department of Epidemiology
[3] Oregon Health & Science University,Department of Public Health and Preventive Medicine
[4] Oregon Health & Science University,Center for Health Care Ethics
来源：
Blood Cancer Journal | / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
    Lammers, Austin
    Wang, Ruibin
    Cetnar, Jeremy
    Prasad, Vinay
    BLOOD CANCER JOURNAL, 2017, 7
  • [2] Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration
    Tibau, Ariadna
    Ocana, Alberto
    Anguera, Georgia
    Seruga, Bostjan
    Templeton, Arnoud J.
    Barnadas, Agusti
    Amir, Eitan
    JAMA ONCOLOGY, 2016, 2 (06) : 744 - 750
  • [3] Food and Drug Administration approval process for ophthalmic drugs in the US
    Lloyd, Rhea
    Harris, Jennifer
    Wadhwa, Sonal
    Chambers, Wiley
    CURRENT OPINION IN OPHTHALMOLOGY, 2008, 19 (03) : 190 - 194
  • [4] Accelerated Approval of Cancer Drugs-Righting the Ship of the US Food and Drug Administration
    DiMagno, Sarah S. P.
    Glickman, Aaron
    Emanuel, Ezekiel J.
    JAMA INTERNAL MEDICINE, 2019, 179 (07) : 922 - 923
  • [5] Timing of US Food and Drug Administration (FDA) cancer drug approvals relative to publication of clinical trial results.
    Khaki, Ali Raza
    Desai, Aakash
    Schoen, Martin W.
    Gyawali, Bishal
    Chen, Eddy J.
    Yang, Peter C.
    Warner, Jeremy Lyle
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals
    Kim, Chul
    Prasad, Vinay
    JAMA INTERNAL MEDICINE, 2015, 175 (12) : 1992 - 1994
  • [7] Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
    Cherla, Avi
    Naci, Huseyin
    Kesselheim, Aaron S.
    Gyawali, Bishal
    Mossialos, Elias
    JAMA INTERNAL MEDICINE, 2021, 181 (04) : 490 - 498
  • [8] Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
    Parikh, Ravi B. B.
    Hubbard, Rebecca A. A.
    Wang, Erkuan
    Royce, Trevor J. J.
    Cohen, Aaron B. B.
    Clark, Amy S. S.
    Mamtani, Ronac
    JAMA ONCOLOGY, 2023, 9 (04) : 567 - 569
  • [9] Novartis faces first hitch in the US Food and Drug Administration approval
    Anon
    Chemistry and Industry (London), 2001, (13):
  • [10] Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
    Mitra-Majumdar, Mayookha
    Gunter, Simon J.
    Kesselheim, Aaron S.
    Brown, Beatrice L.
    Joyce, Krysten W.
    Ross, Murray
    Pham, Catherine
    Avorn, Jerry
    Darrow, Jonathan J.
    JAMA NETWORK OPEN, 2022, 5 (05)
12345